🎉 M&A multiples are live!
Check it out!

Hualan Biological Vaccine Valuation Multiples

Discover revenue and EBITDA valuation multiples for Hualan Biological Vaccine and similar public comparables like GSK India, Prescient Therapeutics, and Imugene.

Hualan Biological Vaccine Overview

About Hualan Biological Vaccine

Hualan Biological Vaccine Inc is engaged in Research, development, production and sales of human vaccines.


Founded

2005

HQ

China
Employees

n/a

Financials

LTM Revenue $190M

LTM EBITDA $141M

EV

$1.1B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Hualan Biological Vaccine Financials

Hualan Biological Vaccine has a last 12-month revenue of $190M and a last 12-month EBITDA of $141M.

In the most recent fiscal year, Hualan Biological Vaccine achieved revenue of $155M and an EBITDA of $49.7M.

Hualan Biological Vaccine expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Hualan Biological Vaccine valuation multiples based on analyst estimates

Hualan Biological Vaccine P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $332M $155M XXX XXX XXX
Gross Profit $222M $293M XXX XXX XXX
Gross Margin 67% 188% XXX XXX XXX
EBITDA $159M $49.7M XXX XXX XXX
EBITDA Margin 48% 32% XXX XXX XXX
Net Profit $71.6M $118M XXX XXX XXX
Net Margin 22% 76% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Hualan Biological Vaccine Stock Performance

As of April 15, 2025, Hualan Biological Vaccine's stock price is CNY 16 (or $2).

Hualan Biological Vaccine has current market cap of CNY 9.7B (or $1.3B), and EV of CNY 7.9B (or $1.1B).

See Hualan Biological Vaccine trading valuation data

Hualan Biological Vaccine Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.1B $1.3B XXX XXX XXX XXX $0.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Hualan Biological Vaccine Valuation Multiples

As of April 15, 2025, Hualan Biological Vaccine has market cap of $1.3B and EV of $1.1B.

Hualan Biological Vaccine's trades at 5.7x LTM EV/Revenue multiple, and 7.7x LTM EBITDA.

Analysts estimate Hualan Biological Vaccine's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Hualan Biological Vaccine and 10K+ public comps

Hualan Biological Vaccine Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.1B XXX XXX XXX
EV/Revenue 7.0x XXX XXX XXX
EV/EBITDA 21.8x XXX XXX XXX
P/E 47.0x XXX XXX XXX
P/E/Growth 0.5x XXX XXX XXX
EV/FCF 18.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Hualan Biological Vaccine Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Hualan Biological Vaccine Valuation Multiples

Hualan Biological Vaccine's NTM/LTM revenue growth is 51%

Hualan Biological Vaccine's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Hualan Biological Vaccine's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Hualan Biological Vaccine's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Hualan Biological Vaccine and other 10K+ public comps

Hualan Biological Vaccine Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -53% XXX XXX XXX XXX
EBITDA Margin 32% XXX XXX XXX XXX
EBITDA Growth -69% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 83% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 44% XXX XXX XXX XXX
G&A Expenses to Revenue 5% XXX XXX XXX XXX
R&D Expenses to Revenue 14% XXX XXX XXX XXX
Opex to Revenue 66% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Hualan Biological Vaccine Public Comps

See public comps and valuation multiples for Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
CSL XXX XXX XXX XXX XXX XXX
Imugene XXX XXX XXX XXX XXX XXX
Prescient Therapeutics XXX XXX XXX XXX XXX XXX
GSK India XXX XXX XXX XXX XXX XXX
AstraZeneca India XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Hualan Biological Vaccine M&A and Investment Activity

Hualan Biological Vaccine acquired  XXX companies to date.

Last acquisition by Hualan Biological Vaccine was  XXXXXXXX, XXXXX XXXXX XXXXXX . Hualan Biological Vaccine acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Hualan Biological Vaccine

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Hualan Biological Vaccine

When was Hualan Biological Vaccine founded? Hualan Biological Vaccine was founded in 2005.
Where is Hualan Biological Vaccine headquartered? Hualan Biological Vaccine is headquartered in China.
Is Hualan Biological Vaccine publicy listed? Yes, Hualan Biological Vaccine is a public company listed on SHE.
What is the stock symbol of Hualan Biological Vaccine? Hualan Biological Vaccine trades under 301207 ticker.
When did Hualan Biological Vaccine go public? Hualan Biological Vaccine went public in 2022.
Who are competitors of Hualan Biological Vaccine? Similar companies to Hualan Biological Vaccine include e.g. CSL, Imugene, Prescient Therapeutics, GSK India.
What is the current market cap of Hualan Biological Vaccine? Hualan Biological Vaccine's current market cap is $1.3B
What is the current revenue of Hualan Biological Vaccine? Hualan Biological Vaccine's last 12-month revenue is $190M.
What is the current EBITDA of Hualan Biological Vaccine? Hualan Biological Vaccine's last 12-month EBITDA is $141M.
What is the current EV/Revenue multiple of Hualan Biological Vaccine? Current revenue multiple of Hualan Biological Vaccine is 5.7x.
What is the current EV/EBITDA multiple of Hualan Biological Vaccine? Current EBITDA multiple of Hualan Biological Vaccine is 7.7x.
What is the current revenue growth of Hualan Biological Vaccine? Hualan Biological Vaccine revenue growth between 2023 and 2024 was -53%.
Is Hualan Biological Vaccine profitable? Yes, Hualan Biological Vaccine is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.